S. Di Pietro

Results of Chemotherapy in Breast Cancer. Study Group for Therapy of Breast Cancer, Cancer Chemotherapy Committee, Italian Society of Cancerology

A summary of the results obtained by the Italian Breast Cancer Group in 122 patients with advanced breast cancer randomized over four different treatments: testosterone propionate, given i.m. 3 times a week at the dose of 100 mg per injection; cyclophosphamide, administered i.m. 25 times a month at the dose of 100 mg/day; testosterone + cyclophosphamide i.m. at the above doses; HMNT (4-hydroxy-17 methyl-19-nortestosterone) given i.m. 3 times a week at the dose of 100 mg/day. The criteria for patient selection and methods of evaluation were, with some modifications, these used by the American Breast Cancer Group. Objective improvements were observed in 26.9% of patients treated with testosterone propionate, in 15.6% of patients treated with cyclophosphamide, in 23.5% of those treated with testosterone + cyclophosphamide and in 20% of patients treated with HMNT. The most interesting result, worth of further evaluation, is that observed with the combined testosterone + cyclophosphamide therapy, which yielded the highest number of objective improvements in patients in menopause for less than one year.

Effetti Anabolizzanti Del 4-Cloro-Testosterone Acetato in Portatori di Neoplasie Maligne: (prima e dopo l'intervento chirurgico)

The treatment with 4-chloro-testosterone acetate exerted, in 10 patients bearing malignant tumours or operated upon, a manifest proteoanabolic effect, with increase in the body weight, augmented proteinemia, retention of urea and of the other catabolites of the protein turnover and improvement of the general conditions. No unpleasant side effects were observed.